Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.
Authors
- M. Hussain
- David G. Russell (ORCID: https://orcid.org/0000-0002-9748-750X)
- Gabriel P. Haas
- Taro Iguchi
- Matt Rosales
- Nicolas Mottet
- Cora N. Sternberg
- Arun A. Azad
- Fred Saad
- Arnulf Stenzl
- Andrew J. Armstrong
Institutions
- Northwestern University (US)
- Kanazawa Medical University (JP)
- The University of Melbourne (AU)
- Pfizer (United States) (US)
- Cornell University (US)
- Peter MacCallum Cancer Centre (AU)
- Duke Medical Center (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Astellas Pharma (United States) (US)
- Weill Cornell Medicine (US)
- Université de Montréal (CA)
- University of Tübingen (DE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1200/jco-24-02829
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00